Temsirolimus, a rapamycin (sirolimus) derivative, also known as CCI-779, is an mTOR inhibitor with anti-cancer activity. Temsirolimus down-regulated the mTOR signaling intermediate phospho-S6 in xenografted human ALL. Temsirolimus has been shown to reverse cisplatin resistance in small cell lung cancer cell lines selected for cisplatin resistance and in cell lines derived from patients who failed cisplatin therapy.

CCI-779, Torisel

≥99%

Soluble in DMSO at 200 mg/ml; soluble in ethanol at 200 mg/ml; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. 

White to off-white solid.

Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.

1. Wan, X., et al. Neoplasia 8: 394-401 (2006).
2. Teachey, D.T., et al. Blood 107: 1149-1155 (2006).
3. Wu, C., et al. Mol. Cancer 4: 25-34 (2005).

Kinase

Inhibitor